Business Wire

Armis Blocks 99% of Cyber Attacks and Delivers 351% ROI, Omdia Finds

20.1.2026 14:00:00 CET | Business Wire | Press Release

Share

Armis, the cyber exposure management & security company, today announced the findings of a new report by technology research and advisory firm, Omdia, analyzing the economic benefits of Armis Centrix™, the Armis Cyber Exposure Management Platform. Analysts found that Armis enables global organizations to achieve 351% annual ROI by combining comprehensive cyber risk management with streamlined operations and significant cost savings.

“This study validates the transformative, quantifiable business impact of Armis’ comprehensive Cyber Exposure Management Platform for our customers,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “With Armis, global organizations are translating security outcomes into operational efficiency, financial savings, and reduced disruption. We’re incredibly proud of the findings of this research, which provide hard data reinforcing that security aligned to exposure and business context is not a cost center, but a measurable driver of business performance.”

Armis Centrix™ acts as a force multiplier for organizations by replacing manual processes with AI-driven intelligence.Customers report superior threat protection, blocking 99% of incoming attacks. By exposing and controlling pathways that adversaries exploit, several organizations noted they are now operating near 100% Zero Trust, effectively neutralizing any potential for lateral movement attacks within their environment.

Additional findings include:

  • Armis Centrix™ improves operational efficiency by 61% through reduced manual effort and faster investigations.
  • Armis customers report uncovering 3X more assets with Armis than they expected. One customer identified 30% more devices than any previous technology had detected, including unmanaged environmental controls on public Wi-Fi.
  • Automated enrichment and exposure-based prioritization have reduced vulnerability workloads of Armis customers by up to 98%, allowing teams to filter out noise and focus exclusively on the highest-risk issues.
  • Customers reported a 90% reduction in Mean Time to Resolution (MTTR), while others noted a reduction in patch cycle time by 59% through precise prioritization and rapid identification of previously invisible, outdated network equipment.
  • Organizations shifted from manual Security Orchestration, Automation, and Response (SOAR) playbooks to 99% automated actions with Armis, turning multi-day processes into second-long tasks.
  • Armis customers saved 10%–15% annually on software licensing by reclaiming unused capacity.
  • Additionally, when preparing for audit cycles, one organization reported saving about 74% of the time they previously spent, enabling them to clear nearly a decade of audit backlog within 18 months. This increased trust in evidence contributed to a 25% reduction in cyber-insurance premiums for the organization.

In addition to the above, Armis customers shared the following as part of this research:

“Armis exposes high-risk segments and legacy systems we could never see before.”

“Just by understanding what we own and the risks, we save about 50% of our time.”

“Identification was instantaneous. We were five or six years behind on network patching, and Armis surfaced it immediately.”

“What used to take weeks now takes days to prepare for an audit.”

“Omdia’s economic analysis revealed that the Armis Centrix™ cyber exposure management platform provided its customers with significant savings and benefits,” shared Jennifer Duey, Senior Economic Validation Analyst at Omdia. “Our financial model shows that Armis Centrix™ can generate significant return on investment through a combination of operational time savings, automation-driven efficiencies, reduced exposure to costly cyber incidents, and avoided spending on insurance and licensing. Organizations seeking to modernize their security operations, strengthen risk management, and improve efficiency without expanding headcount should evaluate whether Armis Centrix™ aligns with their operational and strategic requirements.”

Read the full report, Analyzing The Economic Benefits of Armis Centrix™ Cyber Exposure Management Platform, here.

Find our blog covering these findings in more detail here.

Learn more about Armis Centrix™, the Armis Cyber Exposure Management Platform, here.

About Armis

Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120572661/en/

Contacts

Media Contact:
Rebecca Cradick
Vice President, Global Communications
Armis
pr@armis.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye